Please Note: This trial is no longer enrolling new participants
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer
| Protocol No. | CTO-MK-3475-B15 | Scope | National |
|---|---|---|---|
| Principal Investigator | Nabil Adra | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
